Drug Maker AbbVie Swings to Loss on Charge from Stemcentrx Deal

Competition from lower-cost copies of Abbvie’s top-selling drug and a $4.1 charge billion related to the Stemcentrx acquisition weighed on the company’s latest quarterly financial results.

from WSJ.com: US Business https://on.wsj.com/2sNOo8k
via IFTTT